Keratoconus Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies – Glaukos Corporation, iVeena Delivery Systems, Inc., Laboratoires Thea

March 13 22:28 2023
Keratoconus Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies - Glaukos Corporation, iVeena Delivery Systems, Inc., Laboratoires Thea
The Keratoconus market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Keratoconus pipeline products will significantly revolutionize the Keratoconus market dynamics.

DelveInsight’s “Keratoconus Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Keratoconus, historical and forecasted epidemiology as well as the Keratoconus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


The Keratoconus market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 


To Know in detail about the Keratoconus market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Keratoconus Market Insights


Keratoconus Overview

Keratoconus (KC) is an eye (ocular) disorder characterized by progressive thinning and changes in the shape of the cornea. The cornea is the thin, clear outer layer of the eye and is normally dome-shaped. Slowly progressive thinning of the cornea causes a cone-shaped bulge to develop towards the center of the cornea in the areas of greatest thinning.


Some of the key facts of the Keratoconus Market Report: 

  • The Keratoconus market size was valued approximately USD 2,900 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In August 2022, iVeena entered into a strategic licensing agreement with Glaukos Corporation that grants Glaukos an exclusive global license to develop and commercialize IVMED-80 for Keratoconus
  • In September 2022, CXL Opthhalmics presented its Phase II data and according to the data 80% of patients maintained or improved corrected distance visual acuity 12 months post-operation and 89%of patients 21 years or younger showed stable or improved vision at 12 months
  • Based on this study conducted by Lass et al, it was found that 70% of their 417 patients were between 21 and 40 years of age and only 10% were beyond 50 years
  • The total diagnosed prevalent population of Keratoconus in the seven major markets was estimated to be 1,818,876 in 2021
  • The diagnosed prevalent cases of Keratoconus, in the United States, were found to be 743,178 in 2021
  • Key Keratoconus Companies: Glaukos Corporation, iVeena Delivery Systems, Inc., Laboratoires Thea, Sight Medical Doctors PLLC, Ocular Therapeutix, Inc., and others
  • Key Keratoconus Therapies: Riboflavin, IVMED-80, T4020, Dextenza, Prednisolone Acetate, and others
  • The Keratoconus epidemiology based on gender analyzed that Keratoconus affects both males and females equally


Get a Free sample for the Keratoconus Market Report –


Key benefits of the Keratoconus Market report:

  1. Keratoconus market report covers a descriptive overview and comprehensive insight of the Keratoconus Epidemiology and Keratoconus market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Keratoconus market report provides insights on the current and emerging therapies.
  3. Keratoconus market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Keratoconus market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Keratoconus market.


Download the report to understand which factors are driving Keratoconus epidemiology trends @ Keratoconus Epidemiological Insights 


Keratoconus Market  

The dynamics of the Keratoconus market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

“The US FDA approved therapies for Keratoconus includes Avedro’s Photrexa and Photrexa Viscousas as well as Price Vision Group’s Intacs Device. Photrexa and Photrexa Viscous are photo enhancer indicated for use with the KXL System in corneal collagen cross-linking for the treatment of patients with progressive KC while Intacs are ophthalmic medical inserts designed for the reduction or elimination of myopia and astigmatism in patients with Keratoconus”


Keratoconus Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.


Keratoconus Epidemiology Segmentation:

The Keratoconus market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Keratoconus
  • Prevalent Cases of Keratoconus by severity
  • Gender-specific Prevalence of Keratoconus
  • Diagnosed Cases of Episodic and Chronic Keratoconus


Keratoconus Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Keratoconus market or expected to get launched during the study period. The analysis covers Keratoconus market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Keratoconus Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.


Discover more about therapies set to grab major Keratoconus market share @ Keratoconus market forecast 


Keratoconus Therapies and Key Companies

  • Riboflavin: Glaukos Corporation
  • IVMED-80: iVeena Delivery Systems, Inc.
  • T4020: Laboratoires Thea
  • Dextenza: Sight Medical Doctors PLLC
  • Prednisolone Acetate: Ocular Therapeutix, Inc.


Keratoconus Market Drivers

  • Improvement in treatment and diagnosis options of KC and a large number of agents show promising activity in KC
  • Environmental factors contribute to the wide variation in prevalence. Geographical locations with plenty of sunshine and hot weather have a higher prevalence than locations with colder climates and less sunlight


Scope of the Keratoconus Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Keratoconus Companies: Glaukos Corporation, iVeena Delivery Systems, Inc., Laboratoires Thea, Sight Medical Doctors PLLC, Ocular Therapeutix, Inc., and others
  • Key Keratoconus Therapies: Riboflavin, IVMED-80, T4020, Dextenza, Prednisolone Acetate, and others
  • Keratoconus Therapeutic Assessment: Keratoconus current marketed and Keratoconus emerging therapies
  • Keratoconus Market Dynamics: Keratoconus market drivers and Keratoconus market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Keratoconus Unmet Needs, KOL’s views, Analyst’s views, Keratoconus Market Access and Reimbursement 


Keratoconus Market Barriers

  • Increased public awareness creates a lucrative opportunity for innovation of therapeutics to drive the Keratoconus market
  • There is limited approved therapy for Keratoconus, which opens up a huge platform of new therapies to boon the market
  • Several agents with novel mechanisms of action are also keenly being reconnoitered in ongoing clinical trials


Table of Contents 

1. Keratoconus Market Report Introduction

2. Executive Summary for Keratoconus

3. SWOT analysis of Keratoconus

4. Keratoconus Patient Share (%) Overview at a Glance

5. Keratoconus Market Overview at a Glance

6. Keratoconus Disease Background and Overview

7. Keratoconus Epidemiology and Patient Population

8. Country-Specific Patient Population of Keratoconus 

9. Keratoconus Current Treatment and Medical Practices

10. Keratoconus Unmet Needs

11. Keratoconus Emerging Therapies

12. Keratoconus Market Outlook

13. Country-Wise Keratoconus Market Analysis (2019–2032)

14. Keratoconus Market Access and Reimbursement of Therapies

15. Keratoconus Market Drivers

16. Keratoconus Market Barriers

17.  Keratoconus Appendix

18. Keratoconus Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight


To know more about Keratoconus treatment, visit @ Keratoconus Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States